within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AD06_Nimustine;

model Nimustine
  extends Pharmacolibrary.Drugs.ATC.L.L01AD06;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01AD06</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Nimustine is a nitrosourea alkylating agent used primarily as an anticancer drug. It is mainly used in the treatment of malignant brain tumors such as gliomas. Its use is currently limited to certain countries (notably Japan) and it is not widely approved or marketed in the US or EU. It functions by alkylating DNA and inhibiting tumor cell growth.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameter estimates for nimustine based on published reports for adult cancer patients receiving intravenous administration.</p><h4>References</h4><ol><li><p>Sukhbaatar, A, et al., &amp; Kodama, T (2023). Intralymphatic injection of chemotherapy drugs modulated with glucose improves their anticancer effect. <i>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</i> 165 115110–None. DOI:<a href=&quot;https://doi.org/10.1016/j.biopha.2023.115110&quot;>10.1016/j.biopha.2023.115110</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37421779/&quot;>https://pubmed.ncbi.nlm.nih.gov/37421779</a></p></li><li><p>Sugiyama, S, et al., &amp; Tominaga, T (2007). Safety and efficacy of convection-enhanced delivery of ACNU, a hydrophilic nitrosourea, in intracranial brain tumor models. <i>Journal of neuro-oncology</i> 82(1) 41–47. DOI:<a href=&quot;https://doi.org/10.1007/s11060-006-9247-5&quot;>10.1007/s11060-006-9247-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17031554/&quot;>https://pubmed.ncbi.nlm.nih.gov/17031554</a></p></li><li><p>Zhang, R, et al., &amp; Tominaga, T (2014). Concentration rather than dose defines the local brain toxicity of agents that are effectively distributed by convection-enhanced delivery. <i>Journal of neuroscience methods</i> 222 131–137. DOI:<a href=&quot;https://doi.org/10.1016/j.jneumeth.2013.11.004&quot;>10.1016/j.jneumeth.2013.11.004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24269253/&quot;>https://pubmed.ncbi.nlm.nih.gov/24269253</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Nimustine;
